The small decline in market price for the last few months may raise some interest from investors as it closed today at a share price of 171.13 on 854573.000 in trading volume. The company executives did not add much value to Vertex Pharmaceuticals investors in September. However, diversifying your holdings with Vertex Pharmaceuticals Incorpor or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.7694. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. This diagnostics interface makes it easy to digest most current publicly released information about Vertex Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Vertex Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency. Also please take a look at World Market Map.
About 97.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.79. Vertex Pharmaceuticals recorded earning per share (EPS) of 8.52. The entity had not issued any dividends in recent years. The firm had 2:1 split on 2000-08-24. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people. For more information please call Jeffrey Leiden at 617 341-6100 or visit www.vrtx.com.
Vertex Pharmaceuticals Alerts
Vertex Pharmaceuticals generates negative expected return over the last 30 days
The company currently falls under 'Large-Cap' category with current market capitalization of 43.37 B.
The company has Profit Margin (PM) of 64.13 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 29.0 % which suggests for every 100 dollars of sales it generated a net operating income of 0.29.
Vertex Pharmaceuticals has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
As of 16 of October Vertex Pharmaceuticals has Risk Adjusted Performance of 0.0114, Coefficient Of Variation of 13767.41 and Semi Deviation of 1.47. In relation to Fundamental Indicators, Macroaxis technical analysis interface makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals as well as the relationship between them. In other words you can use this information to find out if the company will indeed mirror its model of past prices and volume data or the prices will eventually revert. We found nineteen technical drivers for Vertex Pharmaceuticals Incorpor which can be compared to its competition. Please validate Vertex PharmaceuticalsValue At Risk as well as the relationship between Semi Variance and Kurtosis to decide if Vertex Pharmaceuticals is priced more or less accurately providing market reflects its prevalent price of 172.41 per share. Given that Vertex Pharmaceuticals has Jensen Alpha of 0.0206, we advise you double-check Vertex Pharmaceuticals Incorpor current market performance to make sure the company can sustain itself at future point.
Vertex Pharmaceuticals Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Weighted Moving Average calculates a weight for each value in Vertex Pharmaceuticals price series with the more recent values given greater weights. View also all equity analysis or get more info about weighted moving average overlap studies indicator.